Arrowhead Pharmaceuticals Inc (ARWR)

1.56
0.06 3.60
NASDAQ : Health Care
Prev Close 1.51
Open 1.51
Day Low/High 1.50 / 1.64
52 Wk Low/High 3.07 / 9.36
Volume 1.12M
Avg Volume 807.30K
Exchange NASDAQ
Shares Outstanding 74.77M
Market Cap 112.16M
EPS -1.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Arrowhead Reports Fiscal 2017 Second Quarter Results

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR), today announced financial results for its fiscal 2017 second quarter ended March 31, 2017.

Arrowhead Pharmaceuticals To Webcast Fiscal 2017 Second Quarter Results

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on Wednesday, May 3, 2017, at 4:30 p.

Arrowhead Pharmaceuticals Presents ARC-AAT Clinical Data At The International Liver Congress™

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) presented clinical data from a Phase 1a/1b study of ARC-AAT, the company's prior generation investigational medicine that was being studied for the treatment of liver disease...

Arrowhead Presents ARC-520 And ARC-521 Clinical Data At The International Liver Congress™

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented clinical data from a Phase 2 study of ARC-520 and a Phase 1/2 study of ARC-521, the company's prior generation investigational medicines that were being studied...

Arrowhead Pharmaceuticals Announces Presentations At The International Liver Congress™

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will present clinical data on ARC-520, ARC-521, and ARC-AAT, the company's prior generation investigational medicines that were being studied for the...

Arrowhead Pharmaceuticals Adopts Stockholder Rights Agreement

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that on March 21, 2017 it entered into a stockholder rights agreement in accordance with an authorization and declaration from its board of directors of a...

Take a Look at These Stocks Poised to Trade Higher

Take a Look at These Stocks Poised to Trade Higher

These 5 stocks under $10 look poised to potentially trade higher.

These 5 Stocks Under $10 Could Explode Higher

These 5 Stocks Under $10 Could Explode Higher

Here's a technical look at how to trade several under $10 stocks that could trigger big breakout trades soon.

Arrowhead Reports Fiscal 2017 First Quarter Results

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2017 first quarter ended December 31, 2016.

Premarket Biotech Movers: Synergy, Arrowhead, BioCryst

Premarket Biotech Movers: Synergy, Arrowhead, BioCryst

Synergy Pharmaceuticals, Arrowhead Pharmaceuticals and BioCryst Pharmaceuticals were among the biotech stock movers in premarket trading on Wednesday.

Arrowhead Pharmaceuticals To Webcast Fiscal 2017 First Quarter Results

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on Monday, February 6, 2017, at 4:30 p.

Robbins Arroyo LLP: Arrowhead Pharmaceuticals, Inc. (ARWR) Misled Shareholders According To A Recently Filed Class Action

Robbins Arroyo LLP: Arrowhead Pharmaceuticals, Inc. (ARWR) Misled Shareholders According To A Recently Filed Class Action

Shareholder rights law firm, Robbins Arroyo LLP, announces that a class action complaint was filed against Arrowhead Pharmaceuticals, Inc.

These 3 Biotech Stocks Are Already Moving Wildly on Thursday

These 3 Biotech Stocks Are Already Moving Wildly on Thursday

Here are some names that have caught our eye.

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Arrowhead Pharmaceuticals, Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of January 17, 2017 - ARWR

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Arrowhead Pharmaceuticals, Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of January 17, 2017 - ARWR

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Arrowhead Pharmaceuticals, Inc.

Arrowhead Provides Response To New Minority Shareholder Announcement

Arrowhead Provides Response To New Minority Shareholder Announcement

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today responded to the announcement by Silence Therapeutics plc that it acquired, in the open-market, an equity stake of 6,000,359 Arrowhead shares, representing 8.

DEADLINE ALERT: Brower Piven Reminds Investors Of The January 16, 2017 Deadline In Class Action Lawsuit And Encourages Investors With Losses In Excess Of $100,000 From Investment In Arrowhead Pharmaceuticals, Inc. To Contact The Firm

DEADLINE ALERT: Brower Piven Reminds Investors Of The January 16, 2017 Deadline In Class Action Lawsuit And Encourages Investors With Losses In Excess Of $100,000 From Investment In Arrowhead Pharmaceuticals, Inc. To Contact The Firm

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf...

ARWR SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Shareholders Of A Class Action Involving Arrowhead Pharmaceuticals, Inc. And A Lead Plaintiff Deadline Of January 17, 2017

ARWR SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Shareholders Of A Class Action Involving Arrowhead Pharmaceuticals, Inc. And A Lead Plaintiff Deadline Of January 17, 2017

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Central District of California on behalf of investors who purchased Arrowhead Pharmaceuticals, Inc.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Arrowhead Pharmaceuticals, Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of January 17, 2017

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Arrowhead Pharmaceuticals, Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of January 17, 2017

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Arrowhead Pharmaceuticals, Inc.

Glancy Prongay & Murray Announces The Filing Of A Securities Class Action On Behalf Of Arrowhead Pharmaceuticals, Inc. Investors And Encourages Investors To Contact The Firm

Glancy Prongay & Murray Announces The Filing Of A Securities Class Action On Behalf Of Arrowhead Pharmaceuticals, Inc. Investors And Encourages Investors To Contact The Firm

Glancy Prongay & Murray LLP ("GPM") announces that a class action lawsuit has been filed on behalf of investors who purchased Arrowhead Pharmaceuticals, Inc.

ARWR SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Shareholders Of Commencement Of A Class Action Involving Arrowhead Pharmaceuticals, Inc. And A Lead Plaintiff Deadline Of January 17, 2017

ARWR SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Shareholders Of Commencement Of A Class Action Involving Arrowhead Pharmaceuticals, Inc. And A Lead Plaintiff Deadline Of January 17, 2017

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Central District of California on behalf of investors who purchased Arrowhead Pharmaceuticals, Inc.

Arrowhead Reports Fiscal 2016 Year End Results

Arrowhead Reports Fiscal 2016 Year End Results

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2016 fourth quarter and year ended September 30, 2016.

The Worst Biopharma CEOs of 2016 Are ...

The Worst Biopharma CEOs of 2016 Are ...

There was plenty of shame to spread around, but Theranos CEO Elizabeth Holmes' loathsome mix of arrogance, incompetence and duplicity makes her the Worst CEO of 2016.

ARWR NOTICE: Rosen Law Firm Reminds Arrowhead Pharmaceuticals, Inc. Investors Of Important Deadline In Class Action - ARWR

ARWR NOTICE: Rosen Law Firm Reminds Arrowhead Pharmaceuticals, Inc. Investors Of Important Deadline In Class Action - ARWR

Rosen Law Firm, reminds purchasers of Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals To Webcast Fiscal 2016 Year End Results

Arrowhead Pharmaceuticals To Webcast Fiscal 2016 Year End Results

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on Wednesday, December 14, 2016, at 4:30 p.

The Law Offices Of Howard G. Smith Announces The Filing Of A Securities Class Action On Behalf Of Arrowhead Pharmaceuticals, Inc. Investors And Encourages Investors To Contact The Firm

The Law Offices Of Howard G. Smith Announces The Filing Of A Securities Class Action On Behalf Of Arrowhead Pharmaceuticals, Inc. Investors And Encourages Investors To Contact The Firm

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharma Shares Destroyed by Development Announcement

Arrowhead Pharma Shares Destroyed by Development Announcement

The company has seen shares fall 60% since market's close Tuesday.

Arrowhead Pharmaceuticals Focuses Resources On Subcutaneous And Extra-Hepatic RNAi Therapeutics

Arrowhead Pharmaceuticals Focuses Resources On Subcutaneous And Extra-Hepatic RNAi Therapeutics

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced a strategic redeployment of resources to support the development of RNAi therapeutics that utilize the company's new proprietary subcutaneous (subQ) and...

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Arrowhead Pharmaceuticals, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Arrowhead Pharmaceuticals, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf...

TheStreet Quant Rating: D- (Sell)